Dinarello 1974.

Methods	RCT: separate course of colchicine and placebo were administrated in random order, 28 days for a course with a total of 60 courses. Cross‐over design. Location: USA. 2 centres.
Participants	11 adults with a history of frequent attacks and characteristics of FMF. Age: unclear. Gender: unclear.
Interventions	Intervention: 0.6 mg colchicine 3 times daily for 28 days (1 course). Control: matching placebo.
Outcomes	Frequency of attacks. Timing of FMF attacks. Adverse events. Outcomes measured at 11 months.
Notes	The outcome data could not be distinguished among each phase.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Separate courses of colchicine, 0.6‐mg tablets, and placebo were administered in random order", however, the exactly randomization method was unclear.
Allocation concealment (selection bias)	Unclear risk	The exactly allocation method was unclear.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The tablets were bottled, coded and dispensed by the Pharmaceutical Development Service at the National Institutes of Health."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Whether outcome assessment was blinded was unclear.
Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: "Six of the 11 patients had completed the study at the time it was terminated, whereas none of the remaining five patients had experienced a sufficient number of attacks for therapy to be considered either a success or a failure."
Selective reporting (reporting bias)	Unclear risk	Protocol could not be reviewed; moreover, the methods section did not predefine outcome measurements.
Other bias	High risk	The baseline characteristics of each participant were not described.